Catalent and Humanigen, Inc. have expanded their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. Recent data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, showed the majority had rapid recovery and hospital discharge. A Phase III study is currently underw...